Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care

Liana G. Apostolova, Janelle M. Haider, Naira Goukasian, Gil D. Rabinovici, Gael Chételat, John M. Ringman, Sarah Kremen, Joshua D. Grill, Lucas Restrepo, Mario F. Mendez, Daniel H. Silverman

Research output: Contribution to journalArticle

Abstract

Introduction The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. Methods Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. Results Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group. Discussion The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.

Original languageEnglish (US)
Pages (from-to)15-22
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume5
DOIs
StatePublished - Jan 1 2016

Fingerprint

Amyloid
Patient Care
Therapeutics
Demography

Keywords

  • Alzheimer's disease (AD)
  • Amyloid
  • Appropriate use criteria (AUC)
  • Mild cognitive impairment (MCI)
  • Positron emission tomography (PET)

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Critical review of the Appropriate Use Criteria for amyloid imaging : Effect on diagnosis and patient care. / Apostolova, Liana G.; Haider, Janelle M.; Goukasian, Naira; Rabinovici, Gil D.; Chételat, Gael; Ringman, John M.; Kremen, Sarah; Grill, Joshua D.; Restrepo, Lucas; Mendez, Mario F.; Silverman, Daniel H.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 5, 01.01.2016, p. 15-22.

Research output: Contribution to journalArticle

Apostolova, LG, Haider, JM, Goukasian, N, Rabinovici, GD, Chételat, G, Ringman, JM, Kremen, S, Grill, JD, Restrepo, L, Mendez, MF & Silverman, DH 2016, 'Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 5, pp. 15-22. https://doi.org/10.1016/j.dadm.2016.12.001
Apostolova, Liana G. ; Haider, Janelle M. ; Goukasian, Naira ; Rabinovici, Gil D. ; Chételat, Gael ; Ringman, John M. ; Kremen, Sarah ; Grill, Joshua D. ; Restrepo, Lucas ; Mendez, Mario F. ; Silverman, Daniel H. / Critical review of the Appropriate Use Criteria for amyloid imaging : Effect on diagnosis and patient care. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2016 ; Vol. 5. pp. 15-22.
@article{616e7dd8851b4cc49acde9251e5b0740,
title = "Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care",
abstract = "Introduction The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. Methods Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. Results Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group. Discussion The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.",
keywords = "Alzheimer's disease (AD), Amyloid, Appropriate use criteria (AUC), Mild cognitive impairment (MCI), Positron emission tomography (PET)",
author = "Apostolova, {Liana G.} and Haider, {Janelle M.} and Naira Goukasian and Rabinovici, {Gil D.} and Gael Ch{\'e}telat and Ringman, {John M.} and Sarah Kremen and Grill, {Joshua D.} and Lucas Restrepo and Mendez, {Mario F.} and Silverman, {Daniel H.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.dadm.2016.12.001",
language = "English (US)",
volume = "5",
pages = "15--22",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Critical review of the Appropriate Use Criteria for amyloid imaging

T2 - Effect on diagnosis and patient care

AU - Apostolova, Liana G.

AU - Haider, Janelle M.

AU - Goukasian, Naira

AU - Rabinovici, Gil D.

AU - Chételat, Gael

AU - Ringman, John M.

AU - Kremen, Sarah

AU - Grill, Joshua D.

AU - Restrepo, Lucas

AU - Mendez, Mario F.

AU - Silverman, Daniel H.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. Methods Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. Results Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group. Discussion The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.

AB - Introduction The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. Methods Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. Results Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group. Discussion The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.

KW - Alzheimer's disease (AD)

KW - Amyloid

KW - Appropriate use criteria (AUC)

KW - Mild cognitive impairment (MCI)

KW - Positron emission tomography (PET)

UR - http://www.scopus.com/inward/record.url?scp=85006957561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006957561&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2016.12.001

DO - 10.1016/j.dadm.2016.12.001

M3 - Article

AN - SCOPUS:85006957561

VL - 5

SP - 15

EP - 22

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -